1. Home
  2. NXGL vs MBIO Comparison

NXGL vs MBIO Comparison

Compare NXGL & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexGel Inc

NXGL

NexGel Inc

HOLD

Current Price

$0.57

Market Cap

4.9M

Sector

Health Care

ML Signal

HOLD

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.77

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXGL
MBIO
Founded
1997
2015
Country
United States
United States
Employees
19
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
5.1M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
NXGL
MBIO
Price
$0.57
$0.77
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$2.00
N/A
AVG Volume (30 Days)
105.0K
57.6K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$50.77
N/A
Revenue Next Year
$46.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.53
52 Week High
$2.89
$7.00

Technical Indicators

Market Signals
Indicator
NXGL
MBIO
Relative Strength Index (RSI) 46.97 61.11
Support Level $0.48 $0.69
Resistance Level $0.64 $0.80
Average True Range (ATR) 0.04 0.07
MACD 0.00 0.01
Stochastic Oscillator 43.31 87.70

Price Performance

Historical Comparison
NXGL
MBIO

About NXGL NexGel Inc

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: